Answers are grounded in this paper and cite their sources.
BACKGROUND: Fatty acid synthase (FASN) is overexpressed in cancer cells, which sustains their elevated demands for membrane synthesis, energy metabolism, and protein biosynthesis. FASN overexpression may serve as a promising therapeutic target for cancer treatment and a key modulator of chemotherapy resistance. This study aimed to explore whether tag single-nucleotide polymorphisms (tag-SNPs) in the FASN gene are related with treatment response and severe chemotherapy toxicity in patients with non-small cell lung cancer (NSCLC) receiving platinum-based regimens. METHODS: A multivariable logistic regression model was applied to evaluate the associations between four tag-SNPs of the FASN gene and clinical outcomes in a cohort of 437 Chinese patients with NSCLC. RESULTS: The variant homozygotes of FASN rs1140616 and rs4246445 were significantly associated with poor treatment response in advanced NSCLC patients undergoing first-line platinum-based chemotherapy compared with wild-type homozygotes. FASN rs1140616, rs2228309, and rs4246445 polymorphisms were significantly related with an increased risk of grade 3-4 thrombocytopenia. FASN rs2228309 variant was linked to a higher incidence of grade 3-4 anemia. CONCLUSION: These findings highlight the critical involvement of the lipid metabolism pathway in platinum chemotherapy resistance and toxicity in NSCLC. Notably, this study addresses a key research gap in the field, as most existing relevant evidence is restricted to in vitro preclinical models.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: